3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Primary Myelofibrosis
13
Myeloproliferative Disorders
10
Polycythemia Vera
9
Leukemia, Myeloid, Acute
9
Myelodysplastic Syndromes
6
Graft vs Host Disease
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia
5
Thrombocythemia, Essential
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Myelodysplastic-Myeloproliferative Diseases
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Monocytic, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Interventions
Tamoxifen
12
Specimen Handling
6
Anastrozole
6
Chemotherapy, Adjuvant
5
Radiotherapy
4
Letrozole
4
afimoxifene
3
Mastectomy, Segmental
3
Surgical Procedures, Operative
2
Simvastatin
2
Radiation Dose Hypofractionation
2
Radiation
2
Fish Oils
2
Fatty Acids, Omega-3
2
4,17 beta-dihydroxy-4-androstene-3-one
2
telapristone acetate
1
sargramostim
1
ruxolitinib
1
polyphenon E
1
palbociclib
1
fezolinetant
1
exemestane
1
elacestrant
1
darolutamide
1
bazedoxifene
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
abemaciclib
1
Zoledronic Acid
1
Testosterone
1
Tea
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Intraductal, Noninfiltrating
×
ruxolitinib
×
Clear all
NCT02928978
2026-04-13
TBCRC042
Baylor Breast Care Center
Phase 2
Completed
84 enrolled